Table 3.
Baseline characteristics of patients with or without clinical worsening
| No CW | CW | p | |
|---|---|---|---|
| Number in follow-up | 56 | 13 | |
| Age (years) | 55.1 ± 14.3 | 59.6 ± 11.3 | 0.29 |
| Female (n (%)) | 27 (51.8) | 8 (61.5) | 0.39 |
| BMI (kg/m2) | 27.9 ± 4.9 | 27.4 ± 3.7 | 0.78 |
| Systolic blood pressure (mmHg) | 130.4 ± 21.5 | 127.7 ± 20.7 | 0.69 |
| Diastolic blood pressure (mmHg) | 80.3 ± 14.3 | 79.6 ± 11.2 | 0.88 |
| NYHA functional class (I/II/III/IV) | 2/9/39/6 | 0/3/9/1 | 0.88 |
| 6-MWD (m) | 393 ± 138 | 374 ± 89 | 0.68 |
| NT-pro BNP (pg/mL) | 1092 ± 1132 | 2648 ± 2177 | 0.19 |
| Right-sided heart catheterisation | |||
| PAP mean (mmHg) | 41.9 ± 12.1 | 38.5 ± 11.0 | 0.36 |
| PVR (dyn·s·cm−5) | 534 ± 264 | 467 ± 269 | 0.48 |
| CO (L/min) | 4.7 ± 1.2 | 5.0 ± 1.2 | 0.51 |
| VC (l) | 3.7 ± 1.0 | 3.7 ± 1.4 | 0.83 |
| FEV1 (%) | 87.8 ± 17.0 | 90.4 ± 22.3 | 0.66 |
| pO2 (kPa) | 9.2 ± 2.3 | 9.0 ± 1.2 | 0.77 |
| Saturation (%) | 93.4 ± 4.9 | 94.1 ± 1.6 | 0.70 |
| Follow up (years) | 3.4 ± 2.2 | 5.1 ± 1.8 | 0.02 |
CW = clinical worsening; BMI = body mass index; NYHA FC = New York Heart Association Functional Class; 6-MWD = six minute walk distance; NT-pro BNP = N-terminal pro brain natriuretic peptide; Creat = creatinine; PAP mean = mean pulmonary artery pressure; PVR = pulmonary vascular resistance; CO = cardiac output; VC = vital capacity; FEV1 = forced expiratory volume in 1 s; pO2 = O2-pressure